Phase 3 Topline Data

TRIUMPH-4 Trial Results: Retatrutide Phase 3 Data 2026 (Honest Breakdown)

Updated 2026-05-06 · 12 min read · Sources peer-reviewed where available

Eli Lilly's late-2025 / early-2026 corporate disclosures pointed to ~28.7% body-weight reduction in the highest-dose arm of TRIUMPH-4 — the Phase 3 retatrutide trial. A secondary readout flagged ~75.8% reduction in knee pain within the osteoarthritis sub-population. These numbers are real, but they require context. Below is the honest breakdown — what's confirmed, what's still pending peer review, and what it actually means for the FDA approval timeline.

TL;DR — 7 facts that matter

✅ TRIUMPH-4 is real (ClinicalTrials.gov NCT05882045) — Phase 3, retatrutide vs placebo in obesity with knee osteoarthritis.
📊 ~28.7% topline weight loss (highest-dose arm) — disclosed by Eli Lilly, peer-review pending.
🦵 ~75.8% knee pain reduction in OA sub-population — same caveat: topline, not yet peer-reviewed.
🧪 Phase 2 reference: ~24% weight loss at 48 weeks (Jastreboff et al, NEJM 2023, PMID 37364103). Phase 3 is consistent.
❌ NOT FDA-approved. NOT legally available for sale in 2026.
⏳ NDA submission estimated Q4 2026 / Q1 2027 (speculative — based on Lilly investor commentary).
⏳ Earliest commercial launch estimated 2027-2028.

What is TRIUMPH-4?

TRIUMPH-4 (ClinicalTrials.gov identifier NCT05882045) is one of the Phase 3 trials in Eli Lilly's retatrutide program. The trial enrolled adults with obesity (BMI ≥30) and concurrent knee osteoarthritis — a deliberately chosen population because GLP-1/GIP/glucagon triple agonism is hypothesized to address both metabolic dysfunction and inflammation-driven joint pain.

Sample size, duration, and detailed inclusion criteria are publicly available on ClinicalTrials.gov. Primary endpoint: change in body weight from baseline. Co-primary or secondary: change in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score and physical function metrics.

TRIUMPH-4 is one piece of a broader Phase 3 program (TRIUMPH-1 through TRIUMPH-5) that Eli Lilly will eventually pool for the New Drug Application (NDA) submission to the FDA.

What the topline data shows

Reported topline figures (Eli Lilly disclosures)

~28.7% mean body-weight reduction at trial endpoint, highest-dose arm.
~75.8% reduction in knee pain (WOMAC pain subscale) in the osteoarthritis sub-population.
Statistically significant vs placebo on both primary and secondary endpoints (per Lilly disclosure).
Side-effect profile reported as "consistent with prior retatrutide studies" — meaning gastrointestinal effects (nausea, vomiting) similar to Phase 2.

Sources: Eli Lilly investor communications and topline press releases. Peer-reviewed publication in a major journal (NEJM, Lancet, JAMA) typically follows 6-18 months after topline disclosure.

The 28.7% figure is striking. By comparison, Phase 3 trials of semaglutide (Wegovy) showed ~15% body-weight reduction in obesity (STEP-1, Wilding et al, NEJM 2021, PMID 33567185). Tirzepatide (Zepbound/Mounjaro) showed ~21% in SURMOUNT-1 (Jastreboff et al, NEJM 2022, PMID 35658024). Retatrutide's triple-receptor mechanism (GLP-1 + GIP + glucagon) was hypothesized to push the curve further — and the data appears to validate that hypothesis.

🔔

Get notified the day FDA approves retatrutide

We track NDA submissions, advisory committee dates, and approval announcements — daily. Free, no spam.

How TRIUMPH-4 compares to Phase 2

Phase 2 retatrutide data is the closest peer-reviewed reference. Jastreboff et al, NEJM 2023 (PMID 37364103; DOI 10.1056/NEJMoa2301972) reported ~24% mean body-weight reduction at 48 weeks in adults with obesity, highest-dose arm.

The Phase 3 TRIUMPH-4 topline of 28.7% is roughly 4-5 percentage points higher than Phase 2 — within the expected range when (a) extending trial duration, (b) refining the dosing schedule, and (c) selecting the optimal patient population. It is not a leap that demands skepticism; it is consistent with what the mechanism of action would predict.

What TRIUMPH-4 does not mean

❌ It does NOT mean retatrutide is FDA-approved. Approval requires the NDA submission, FDA review (typically 10-12 months), and possibly an advisory committee.
❌ It does NOT mean retatrutide is safe for everyone. Phase 3 reports the average; individual safety profiles vary. People with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 are typically excluded from GLP-1/GIP class drugs.
❌ It does NOT mean you should buy "retatrutide" online. Anyone selling retatrutide commercially in 2026 is operating outside FDA-approved channels. The molecule is investigational.
❌ It does NOT mean 28.7% loss for every patient. The figure is a mean. Some patients lost more, some less. Individual results vary significantly.
❌ It does NOT mean the data is final. Topline disclosures are not peer-reviewed publications. The full TRIUMPH-4 paper will include statistical context, sub-group analyses, and adverse event detail not yet public.

Timeline ahead

Based on Eli Lilly's typical regulatory cadence and investor commentary, the realistic timeline (all estimated, not promised) is:

2026 (in progress): Phase 3 program reads out across TRIUMPH-1 through TRIUMPH-5. Full peer-reviewed publications begin.
Q4 2026 / Q1 2027 (estimated): NDA submission to FDA. Lilly has signaled this window in investor calls.
2027 (estimated): FDA review. Standard review = 10 months from NDA acceptance; Priority Review = 6 months. Whether retatrutide gets Priority designation is unknown.
2027 (possibly): Advisory Committee meeting, if FDA requires one. For obesity drugs in this class, AdCom is not always called.
2027-2028 (estimated): Earliest commercial launch. Branded retatrutide enters pharmacies. Initial supply will likely be constrained — see the Wegovy/Zepbound launch precedent.

Track every milestone live on our Retatrutide FDA Approval Tracker — bookmarked update on every official disclosure.

How readers can prepare

Subscribe to the waitlist (form above). We email subscribers ONLY when something material happens — Phase 3 publication, NDA submission, AdCom date, approval, or supply constraint announcements. No daily newsletter spam.
Bookmark the FDA Approval Tracker at /retatrutide-approval-tracker.html — updated as official events happen.
Talk to your physician about whether a currently-approved GLP-1 or GLP-1/GIP option (semaglutide, tirzepatide) is appropriate for you while retatrutide moves through approval. If you're exploring legal options today, compare vetted telehealth providers in our honest 2026 reviews — e.g. GobyMeds (cleanest FDA record, from ~$99/mo) or SHED (premium concierge) — and see real pricing in our retatrutide cost breakdown. (Affiliate links — see disclosure.)
Read the full Phase 2 paper when you have time — Jastreboff 2023 NEJM is available open-access on PubMed.
Be skeptical of any "buy retatrutide" offer in 2026. The molecule is not yet legally available. Sellers are either lying about what's in the vial or operating outside compliance.

Frequently asked

Is retatrutide FDA-approved after TRIUMPH-4?

No. As of May 2026, retatrutide is still investigational. TRIUMPH-4 is a Phase 3 trial; FDA approval requires NDA submission, FDA review, and (potentially) advisory committee. Earliest approval estimated 2027-2028 — speculative.

Where can I buy retatrutide after the TRIUMPH-4 results?

Nowhere legally. Retatrutide is not yet FDA-approved and not legally available for sale in 2026. Any vendor selling "retatrutide" is operating outside FDA-approved channels. We do not link to any such vendor.

Has TRIUMPH-4 data been peer-reviewed?

The 28.7% topline weight-loss figure was disclosed by Eli Lilly in late 2025 / early 2026 corporate communications. Full peer-reviewed publication in NEJM or Lancet typically follows 6-18 months later. Always wait for peer review before drawing strong conclusions.

How does TRIUMPH-4 compare to Phase 2?

Phase 2 (Jastreboff et al, NEJM 2023, PMID 37364103) showed ~24% weight loss at 48 weeks in obesity. Phase 3 TRIUMPH-4 topline of 28.7% is consistent or slightly higher — within expected range when extending duration and refining dosing. Final Phase 3 paper will provide statistical context.

Sources & clinical references

ClinicalTrials.gov — NCT05882045 (TRIUMPH-4 trial registration)
Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. NEJM 2023. PMID 37364103 · DOI 10.1056/NEJMoa2301972
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021. PMID 33567185
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. PMID 35658024
Eli Lilly investor communications and topline press releases (2025-2026). Peer-reviewed publication of TRIUMPH-4 expected 2026-2027.

Disclaimer: Educational content only. Not medical advice. Retatrutide is investigational and NOT FDA-approved. Topline trial data is preliminary and not yet peer-reviewed. Individual results vary significantly. Consult your physician before starting any medication.